Amgen Axes Development of Early-Stage Bispecific T-Cell Engager for Solid Tumors

Amgen on Monday terminated the development of its investigational bispecific T-cell engager AMG 794, which it had been studying in a Phase I trial for several solid tumors including non-small cell lung cancer and epithelial ovarian cancer.